• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Sleep apnea dev NightBalance raises $13.9m in Series B

Sleep apnea dev NightBalance raises $13.9m in Series B

July 5, 2016 By Fink Densford

NightBalance

Dutch sleep apnea device developer NightBalance said today it raised $13.9 million (EU €12.5 million) in a Series B round of financing, and it added 4 new members to its board, including new board chair Jan Keltjens.

NightBalance produces the Sleep Position Trainer, which is designed to train patients to not sleep on their back to prevent positional obstructive street apnea, the company said. The device is worn on the chest and constantly measures sleep position, “nudging’ the user to change position while leaving the natural sleep pattern unaffected.

The round was led by Inkef Capital and Gilde Healthcare Partners, and joined by existing investors Thuja Capital, Health Innovation Fund and Van Herk Ventures. Inkef’s Dirk Kersen and Gilde’s Pieter van der Meer will join Keltjens and Geoff Waters on the company’s board, NightBalance said.

“We are delighted to welcome Inkef and Gilde to our investor base, and to significantly strengthen our board and management with seasoned industry executives Jan Keltjens, Geoff Waters, and John Lipman. In the EU and U.S. alone, an estimated 25 million people suffer from sleep apnea of which 80% goes undiagnosed or is not helped with current treatments; our mission is to change these lives. This financing will allow us to move full steam ahead and increase our market penetration in Europe’s billion dollar market, and – under the leadership of John Lipman who joins us from Apnicure Inc. – build the necessary infrastructure to access the U.S. market,” CEO Eline Vrijland-van Beest said in a press release.

Proceeds from the round are slated to be used to expand commercialization of the company’s Sleep Position Trainer in Europe and to aid in preparation for entry into the U.S. market. The company said it is planning for clinical trials in the U.S., and that it is preparing for 510(k) clearance filing with the FDA.

“NightBalance stands out in the emerging field of novel sleep apnea technologies with their continued commitment to generate high-quality and actionable clinical data sets underpinning the ease of use and efficacy of the Sleep Position Trainer. I look forward to working with Eline and her team as well as the Board to help navigate the company’s important next phase of growth and development,” board chair Keltjens said in prepared remarks.

Filed Under: Business/Financial News, Respiratory Tagged With: NightBalance BV

More recent news

  • A new way to monitor glucose: Glucotrack explains 3-year CBGM implant technology
  • Dexcom continues advances in AI for CGM, type 2 diabetes awareness
  • Tandem continues to deliver more options, benefits for those with diabetes
  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy